RELIEF: Remibrutinib in Chronic Spontaneous Urticaria: Early Real World Effectiveness and Satisfaction Survey
Novartis Pharmaceuticals
Summary
This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.
Eligibility
- Age range
- 18–100 years
- Sex
- All
- Healthy volunteers
- No
Inclusion criteria: Healthcare provider (HCP) participants eligible to refer patients for inclusion in this study must meet all the following criteria: 1. Have an active medical license and be board certified/board eligible allergist or dermatologist in the US. Nurse practitioners and physician assistant practicing in allergy and dermatology are eligible. 2. Manage CSU patients within their practice. 3. Enrolled in the research network or are referred HCPs who agree to participate. 4. Have the requisite patient population based on study inclusion/exclusion criteria. Patients eligible for…
Location
- NovartisEast Hanover, New Jersey